International journal of hematologic oncology · 2022
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saydam Guray, Ali Ridvan, Demir Ahmet Muzaffer, Eskazan Ahmet Emre, Guvenc Birol, Haznedaroglu Ibrahim Celalettin, Ozcan Mehmet Ali, Salim Ozan, Sonmez Mehmet, Tuglular Ayse Tulin, Turgut Mehmet, Unal Ali, Aver Birkan, Bozkurt Sirac, Ozdengulsun Begum, Ilhan Osman
Аннотация
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clinical approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient's individual condition.